CureDuchenne raises more than $1.35 million towards a cure with the Napa in Newport at the Pendry

CureDuchenne and Vintner Chair Alpha Omega recently hosted the 10th Annual Napa in Newport at the Pendry Newport Beach on Saturday, April 20. The event raised more than $1.35 million towards finding and funding a cure for Duchenne muscular dystrophy, a progressive neuromuscular disease.

Napa in Newport has become Southern California’s quintessential wine event, blending the prestige of Napa Valley with the passionate pursuit of a cure for Duchenne muscular dystrophy, one of the most common and severe forms of muscular dystrophy. This year’s gala commemorated a decade-long journey of philanthropy, community and exquisite wine, and featured an unrivaled collection of high-quality, limited-production wines from dedicated Napa Valley vintners.

Click on photo for a larger image

Photos courtesy of CureDuchenne

(L-R) Cary Hyden, Bre Cox, Debra Miller (founder and CEO of CureDuchenne) and Paul Miller

Guests began the evening with a Grand Tasting with 29 vintners showcasing their finest vintages and enjoyed a gourmet dinner at vintner-hosted tables, with a meal curated by Slanted Door Executive Chef/Founder Charles Phan.

Click on photo for a larger image

(L-R) Debbie Miller, Slanted Door Executive Chef/Founder Charles Phan and Paul Miller

Nashville radio personality and Orange County native Shawn Parr emceed the evening, leading a lively live auction featuring spectacular auction lots that included rare and collectible wines and once-in-a-lifetime experiences.

Click on photo for a larger image

Diane Kemple-Plott and Lance Plott

Event sponsors included Porsche Newport Beach, Porsche Irvine, South Coast Plaza and MWA Luxury.

At the event, CureDuchenne honored Douglas S. Ingram, president and CEO of Sarepta Therapeutics, for his dedication to advancing treatments and support for individuals with Duchenne muscular dystrophy.

Click on photo for a larger image

(L-R) Doug Ingram (president and CEO of Sarepta Therapeutics), Hawken Miller, Debra and Paul Miller

Susan Finazzo, mother of two boys with Duchenne who participated in Sarepta’s gene therapy clinical trial, shared her family’s journey with Duchenne and the urgent need to bring treatments to more individuals with this devastating disease. “I just want my boys to be able to live long enough to enjoy what life is. I want them to have enough time to fall in love, maybe get married, or maybe experience the joy of becoming parents themselves,” said Finazzo.

Click on photo for a larger image

Jeff and Marie Goffman

Debra Miller, founder and CEO of CureDuchenne, shared her reflections on Napa in Newport: “We are so grateful for the generosity of our vintners, sponsors and guests. Over the last decade, Napa in Newport has become not just an event, but a movement that has had tremendous impact. With the significant funds raised at Napa in Newport, we’ve made strategic investments in promising research that has significantly driven scientific progress. There is more hope and progress toward a cure than ever before, but we’re not done until everyone with Duchenne has a transformative treatment.”

Click on photo for a larger image

(L-R) Paul and Debra Miller addressing the crowd

CureDuchenne is a global leader in research, patient care and innovation for improving and extending the lives of those living with Duchenne. To date, Napa in Newport has raised more than $12 million to this effort.

The event concluded with the announcement that the 11th Annual Napa in Newport will be held on March 1, 2025 at Pendry Newport Beach. The 2025 Vintner Chair will be Morlet. Tickets are available at www.napainnewport.org.


Slide

Send this to a friend